Morgan Glascock
Research Subjects
Morgan Glascock has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Jessie Schwartz
Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Center, Seattle, USA
2 shared publications - Parth D. Shah
Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA
2 shared publications - Alison Tytell Brenner
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA
1 shared publication - Catherine Fedorenko
Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA
1 shared publication - Daniel S. Reuland
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA
1 shared publication - Jennifer L. Bacci
University of Washington School of Pharmacy, Seattle, WA
1 shared publication
Latest Publications
- Open Access
- 15 June 2026
- Published by Elsevier in SSRN Electronic Journal
Expanding access to colorectal cancer screening through community pharmacies: study protocol for the PharmFIT™ randomized controlled trial
Background. Colorectal cancer (CRC) is a leading cause of cancer death. Fecal immunochemical test (FIT) screening remains underused, particularly in underserved communities. Community pharmacies are highly accessible and increasingly deliver preventive care, yet pharmacy-based CRC screening has not been tested in a large pragmatic randomized trial with concurrent implementation and economic evaluation. This protocol describes a pragmatic trial testing a pharmacy-based CRC screening intervention using FIT, called PharmFIT™, which integrates community pharmacies into CRC screening pathways for primary care patients due for screening.Methods. PharmFIT™ is a two-arm, pragmatic, hybrid type 1 effectiveness–implementation trial in two geographically disparate states (Washington and North Carolina). Adults aged 45–75 years, due for CRC screening, are randomized (n=1,200) to PharmFIT™ or usual care. In the intervention arm, clinics recommend CRC screening and refer patients to partner pharmacies, and pharmacists counsel patients, dispense FIT kits, and support kit return and follow-up. The primary outcome is completion of any United States Preventive Services Task Force–recommended CRC screening test within 6 months. Secondary outcomes include reach, timeliness of FIT completion and follow-up colonoscopy, and screening differences across patient subgroups. Implementation outcomes (acceptability, appropriateness, feasibility, fidelity, cost) are assessed using mixed methods, and economic analyses estimate intervention implementation costs, incremental cost per additional patient screened, and budget impact conducted from pharmacy and societal perspectives.Conclusions. PharmFIT™ will provide effectiveness, implementation, and cost evidence for pharmacy-based CRC screening, informing the scalability of pharmacist-led cancer prevention within primary care.
- 15 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessExpanding access to colorectal cancer screening through community pharmacies: study protocol for the PharmFIT™ randomized controlled trial
Background. Colorectal cancer (CRC) is a leading cause of cancer death. Fecal immunochemical test (FIT) screening remains underused, particularly in underserved communities. Community pharmacies are highly accessible and increasingly deliver preventive care, yet pharmacy-based CRC screening has not been tested in a large pragmatic randomized trial with concurrent implementation and economic evaluation. This protocol describes a pragmatic trial testing a pharmacy-based CRC screening intervention using FIT, called PharmFIT™, which integrates community pharmacies into CRC screening pathways for primary care patients due for screening.Methods. PharmFIT™ is a two-arm, pragmatic, hybrid type 1 effectiveness–implementation trial in two geographically disparate states (Washington and North Carolina). Adults aged 45–75 years, due for CRC screening, are randomized (n=1,200) to PharmFIT™ or usual care. In the intervention arm, clinics recommend CRC screening and refer patients to partner pharmacies, and pharmacists counsel patients, dispense FIT kits, and support kit return and follow-up. The primary outcome is completion of any United States Preventive Services Task Force–recommended CRC screening test within 6 months. Secondary outcomes include reach, timeliness of FIT completion and follow-up colonoscopy, and screening differences across patient subgroups. Implementation outcomes (acceptability, appropriateness, feasibility, fidelity, cost) are assessed using mixed methods, and economic analyses estimate intervention implementation costs, incremental cost per additional patient screened, and budget impact conducted from pharmacy and societal perspectives.Conclusions. PharmFIT™ will provide effectiveness, implementation, and cost evidence for pharmacy-based CRC screening, informing the scalability of pharmacist-led cancer prevention within primary care.